New Delhi, Feb 19 (IANS) Novartis India shares jumped more than 6 per cent on Monday after the parent company, Novartis AG announced a strategic review of its Indian arm.
Novartis India was trading at Rs 1,100, up 6.23 per cent on BSE. Earlier in the day it hit a 52 week high.
According to reports Dr Reddy’s is likely in a race to acquire Novartis AG’s stake. Dr Reddy’s said: “In this regard, please note that the company does not comment on market speculations and there is currently no such event or information which requires a disclosure under Regulation 30 of the SEBI Listing Regulations. In compliance with Regulation 30 of the SEBI Listing Regulations, the company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.”
Earlier, the board of directors of Novartis India took note of the communication received from Novartis AG, Holding Company & Promoter, regarding their intention to conduct a strategic review to unlock value of their shareholding in the company.
“After some deliberations, the Board agreed to support Novartis AG, as may be required, in evaluating their strategic options”, Novartis India said.
Novartis AG announced a strategic review of Novartis India Limited, a public company listed on Bombay Stock Exchange.
The strategic review will include an assessment of the 70.68 per cent shareholding of Novartis AG in the company.
Novartis India Limited is separate from Novartis Healthcare Private Limited, the wholly owned subsidiary of the Novartis group in India.
Novartis Healthcare Private Limited includes the Novartis Corporate Center in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country.
The strategic review will not impact Novartis Healthcare Private Limited.
“There can be no assurance that the strategic review of Novartis India Limited will be completed in 2024, or that the outcome would result in the implementation of any transaction,” the company said.
“Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years. Today Novartis proudly employs more than 8,100 associates in India,” it said.
(Sanjeev Sharma can be reached at Sanjeev.s@ians.in)
–IANS
biz/san/prw
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
